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Background
The HVTN 503/Phambili trial, a phase IIB study of the
Merck Ad-5 HIV vaccine, suspended enrollment and vac-
cinations following results of the HVTN502/STEP study.
Participants were notified of their treatment allocation
and continue to be followed. We investigated the impact
of the suspension on trial participants' attitudes towards
HIV vaccine trials and scientific research.
Methods
A self-administered questionnaire investigating knowl-
edge and attitudes utilising a five-point likert scale, was
administered 12–18 months post suspension at the 4
Phambili trial sites implementing the latest protocol.
Results
Of 544 participants enrolled at 4 sites, 490 completed the
questionnaire. 51% understood that vaccination, and
31% that enrolment had been permanently discontinued.
Although 85% knew Phambili DSMB recommendations
were based on results of the STEP study, only 51% knew
that the results showed more infections in the vaccine
arm. Although 90% knew they should continue protect-
ing themselves against HIV, only 33% acknowledged tri-
alists' concerns that the vaccine may make them more
susceptible to HIV. Knowledge was similar across sites.
12% had tested for HIV antibodies outside of the trial
before unblinding to establish their treatment allocation.
46% felt disappointed, angry or afraid, primarily because
the vaccine would not prevent HIV in their community.
79% said they would engage in less risk behaviour. 94%
thought the study team had made the correct decision by
unblinding them and 96% thought site-participant com-
munication was appropriate. 91% felt they made the right
decision to enrol in Phambili and 91% planned to con-
tinue attending scheduled visits. 86% support scientific
research and 80% would want to participate in future HIV
vaccine.
Conclusion
Despite site communications, knowledge levels were low.
Importantly, most knew they should continue to protect
themselves against HIV. Although almost half of partici-
pants reported negative feelings, most attitudes towards
trial sites, scientific research and HIV vaccine trials were
positive.
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